Linsitinib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Linsitinib
Linsitinib.svg
Names
IUPAC name
3-[8-Amino-1-(2-phenyl-7-quinolyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol
Other names
OSI-906
Identifiers
867160-71-2 YesY
ChEMBL ChEMBL1091644
ChemSpider 21391708
Jmol-3D images Image
Properties
C26H23N5O
Molar mass 421.49 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R).[1] This prevents tumor cell proliferation and induces tumor cell apoptosis.[2]

Linsitinib was discovered by OSI Pharmaceuticals and is currently in Phase III clinical trials for adrenocortical carcinoma and Phase II clinical trials for lung and ovarian cancers.[3][4]

References[edit]

  1. ^ Mulvihill, MJ; Cooke, A; Rosenfeld-Franklin, M; Buck, E; Foreman, K; Landfair, D; O'Connor, M; Pirritt, C et al. (2009). "Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor". Future medicinal chemistry 1 (6): 1153–71. doi:10.4155/fmc.09.89. PMID 21425998. 
  2. ^ "Linsitinib". NCI Drug Dictionary. National Cancer Institute. Retrieved October 16, 2012. 
  3. ^ "OSI Pharmaceuticals, LLC". Astellas Pharma. Retrieved October 16, 2012. 
  4. ^ "Linsitinib". National Institutes of Health's clinicaltrials.gov. Retrieved October 16, 2012.